Maarten van der Doelen

General discussion and future perspectives

At this moment, lutetium-177 seems to be the preferred radionuclide for PSMA targeting RLT, based on the broader clinical experience and the outcomes of the VISION trial. However, based on several case series, there is a role for 225 Ac-PSMA TAT in mCRPC patients after failure of 177 Lu-PSMA RLT. (3, 125)

8

217